These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 21355825)

  • 1. Audit of safety and quality of the use of enoxaparin for anticoagulation in continuous renal replacement therapy.
    Tsang DJ; Tuckfield A; Macisaac CM
    Crit Care Resusc; 2011 Mar; 13(1):24-7. PubMed ID: 21355825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous renal replacement therapies: anticoagulation in the critically ill at high risk of bleeding.
    Morabito S; Guzzo I; Solazzo A; Muzi L; Luciani R; Pierucci A
    J Nephrol; 2003; 16(4):566-71. PubMed ID: 14696760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enoxaparin vs. unfractionated heparin for anticoagulation during continuous veno-venous hemofiltration: a randomized controlled crossover study.
    Joannidis M; Kountchev J; Rauchenzauner M; Schusterschitz N; Ulmer H; Mayr A; Bellmann R
    Intensive Care Med; 2007 Sep; 33(9):1571-9. PubMed ID: 17563874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is regional citrate superior to systemic heparin anticoagulation for continuous renal replacement therapy? A prospective observational study in an adult regional critical care system.
    Bagshaw SM; Laupland KB; Boiteau PJ; Godinez-Luna T
    J Crit Care; 2005 Jun; 20(2):155-61. PubMed ID: 16139156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intermittent hemodialysis versus continuous renal replacement therapy for acute renal failure in the intensive care unit: an observational outcomes analysis.
    Rauf AA; Long KH; Gajic O; Anderson SS; Swaminathan L; Albright RC
    J Intensive Care Med; 2008; 23(3):195-203. PubMed ID: 18474503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postoperative anticoagulation in vascular surgery: part 1. A retrospective comparison of clinical outcomes for unfractionated heparin versus low-molecular-weight heparin.
    Gramse CA; Hingorani A; Ascher E
    J Vasc Nurs; 2001 Jun; 19(2):42-9; quiz 50-1. PubMed ID: 11395717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermittent versus continuous renal replacement therapy for acute kidney injury patients admitted to the intensive care unit: results of a randomized clinical trial.
    Lins RL; Elseviers MM; Van der Niepen P; Hoste E; Malbrain ML; Damas P; Devriendt J;
    Nephrol Dial Transplant; 2009 Feb; 24(2):512-8. PubMed ID: 18854418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antithrombin supplementation for anticoagulation during continuous hemofiltration in critically ill patients with septic shock: a case-control study.
    du Cheyron D; Bouchet B; Bruel C; Daubin C; Ramakers M; Charbonneau P
    Crit Care; 2006; 10(2):R45. PubMed ID: 16542495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo evaluation of enoxaparin removal by continuous renal replacement therapies with acrylonitrile and polysulfone membranes.
    Isla A; Gascón AR; Maynar J; Arzuaga A; Corral E; Martín A; Solinís MA; Muñoz JL
    Clin Ther; 2005 Sep; 27(9):1444-51. PubMed ID: 16291417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-centre evaluation of anticoagulation in patients receiving continuous renal replacement therapy (CRRT).
    Brophy PD; Somers MJ; Baum MA; Symons JM; McAfee N; Fortenberry JD; Rogers K; Barnett J; Blowey D; Baker C; Bunchman TE; Goldstein SL
    Nephrol Dial Transplant; 2005 Jul; 20(7):1416-21. PubMed ID: 15855212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquired deficit of antithrombin and role of supplementation in septic patients during continuous veno-venous hemofiltration.
    Lafargue M; Joannes-Boyau O; Honoré PM; Gauche B; Grand H; Fleureau C; Rozé H; Janvier G
    ASAIO J; 2008; 54(1):124-8. PubMed ID: 18204328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute renal failure in critically ill surgical patients: persistent lethality despite new modes of renal replacement therapy.
    Eachempati SR; Wang JC; Hydo LJ; Shou J; Barie PS
    J Trauma; 2007 Nov; 63(5):987-93. PubMed ID: 17993940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.
    Stellbrink C; Nixdorff U; Hofmann T; Lehmacher W; Daniel WG; Hanrath P; Geller C; Mügge A; Sehnert W; Schmidt-Lucke C; Schmidt-Lucke JA;
    Circulation; 2004 Mar; 109(8):997-1003. PubMed ID: 14967716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Citrate clearance in children receiving continuous venovenous renal replacement therapy.
    Chadha V; Garg U; Warady BA; Alon US
    Pediatr Nephrol; 2002 Oct; 17(10):819-24. PubMed ID: 12376810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iloprost for additional anticoagulation in continuous renal replacement therapy--a pilot study.
    Birnbaum J; Spies CD; Klotz E; Hein OV; Morgera S; Schink T; Ziemer S; Grund MS; Saalmann R; Kox WJ; Lehmann C
    Ren Fail; 2007; 29(3):271-7. PubMed ID: 17497439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regional citrate anticoagulation using a citrate-based substitution solution for continuous venovenous hemofiltration in cardiac surgery patients.
    Thoenen M; Schmid ER; Binswanger U; Schuepbach R; Aerne D; Schmidlin D
    Wien Klin Wochenschr; 2002 Feb; 114(3):108-14. PubMed ID: 12060967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enoxaparin versus unfractioned heparin as anticoagulant for continuous venovenous hemodialysis: a randomized open-label trial.
    Garcés EO; Victorino JA; Thomé FS; Röhsig LM; Dornelles E; Louzada M; Stifft J; de Holanda F; Veronese FV
    Ren Fail; 2010 Jan; 32(3):320-7. PubMed ID: 20370447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies.
    Spinler SA; Inverso SM; Cohen M; Goodman SG; Stringer KA; Antman EM;
    Am Heart J; 2003 Jul; 146(1):33-41. PubMed ID: 12851605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-Xa monitoring of enoxaparin for acute coronary syndromes in patients with renal disease.
    Ma JM; Jackevicius CA; Yeo E
    Ann Pharmacother; 2004 Oct; 38(10):1576-81. PubMed ID: 15328396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticoagulation in continuous renal replacement therapy.
    Hidalgo N; Hynes-Gay P; Hill S; Burry L
    Dynamics; 2001; 12(4):13-7. PubMed ID: 11845482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.